Clinical Trial

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Study acronym: TITANS
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-11.
Trial Details
NCT Number NCT07652736
Lead Sponsor BeOne Medicines
Conditions Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
Enrollment 440 participants
Start Date 2026-06-05
Primary Completion 2027-11-15 (estimated)
Study Completion 2030-11-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-25